Healthy Performance By S A Druggists Group

24 October 1994

The S A Druggists group's prescription of vigorous market penetration plus sustained productivity improvement produced another healthy performance in the year to August. SAD is one of three major locally-owned drug companies in South Africa.

Results for fiscal 1994 show earnings up 48% to 96 million rand ($26.9 million) on a 17% rise in turnover to 2.15 billion rand. Earnings per share increased 30% to 159.4 cents. The group's operating margin improved 7%. All divisions have contributed to the performance, the company said.

In spite of the significant financing of some 49 million rand required by new ventures during the year, SAD's balance sheet continued to strengthen and gearing was down to a nominal 3.9% at the end of August.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight